The dose distribution in dominant intraprostatic tumour lesions defined by multiparametric MRI and PSMA PET/CT correlates with the outcome in patients treated with primary radiation therapy for prostate cancer

Table 3 Cox-regression analyses considering BRFS

Univariate Cox regression	p value	Multivariate Cox regression (with Gleason and cT stage)	HR (95 CI)	p value
Dose parameters
Dmin DIL-imaging in Gy		Dmin DIL-imaging in Gy
(< 70.6, ≥70.6)	0.023	(< 70.6, ≥70.6)	0.039 (0.2–0.9)	0.036
Dmax DIL-imaging in Gy		Dmax DIL-imaging in Gy
(< 75.8, ≥75.8)	0.013	(< 75.8, ≥75.8)	0.31 (0.1–0.7)	0.009
Dmax SPG in Gy		Dmax SPG in Gy
(< 76, ≥76)	0.006	(< 76, ≥76)	0.32 (0.14–0.8)	0.009
Dmax PG in Gy		Dmax PG in Gy
(< 76, ≥76)	0.006	(< 76, ≥76)	0.32 (0.14–0.8)	0.009

Results of the Cox regression analyses for the influence of different patient, treatment and dose parameters on the BRFS. Cut-off values for respective dose parameters were determined by an explorative analysis. None of the Dmin values were significant in PG and SPG, respectively. None of the binarized Dmean values were significant in any of the three volumes. Gleason score and cT stage were not significant (p < 0.05) in any of the multivariate analyses including dose parameters. Abbreviations: CI confidence interval, HR hazard ratio. Bold = values with p < 0.05

ISSN: 1748-717X